Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | F2R | P25116 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281897 | 1.00 | MAPT (0.68) | MAPTL3MBTL1POLBF2RMEN1 | |
| SCHEMBL7313986 | 0.77 | MAPT (0.70) | MAPTL3MBTL1POLBF2RLMNA | |
| SCHEMBL7313994 | 0.77 | MAPT (0.70) | MAPTL3MBTL1POLBF2RLMNA | |
| SCHEMBL3095935 | 0.76 | MAPT (0.54) | MAPTL3MBTL1POLBF2RMEN1 | |
| SCHEMBL3095929 | 0.76 | MAPT (0.54) | MAPTL3MBTL1POLBF2RMEN1 | |
| SCHEMBL7307640 | 0.75 | MAPT (0.63) | MAPTL3MBTL1POLBF2RLMNA | |
| SCHEMBL4508730 | 0.75 | MAPT (0.67) | MAPTL3MBTL1POLBF2RALDH1A1 | |
| SCHEMBL7307644 | 0.75 | MAPT (0.63) | MAPTL3MBTL1POLBF2RLMNA | |
| SCHEMBL10300780 | 0.75 | F2R (0.82) | MAPTL3MBTL1POLBF2RMEN1 | |
| SCHEMBL2744240 | 0.74 | GSR (0.79) | MAPTL3MBTL1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| EP-1943228-A2 | INHIBITORS OF VIRAL REPLICATION | Intermune, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | MAPT 4203/4885L3MBTL1 1550/4885POLB 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.